# A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

> **NCT05622058** · PHASE1 · TERMINATED · sponsor: **Aileron Therapeutics, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Prevention of Chemotherapy-induced Myelosuppression

## Interventions

- **DRUG:** ALRN-6924
- **DRUG:** TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)

## Key facts

- **NCT ID:** NCT05622058
- **Lead sponsor:** Aileron Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-09
- **Primary completion:** 2023-02-22
- **Final completion:** 2023-02-22
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The study has been terminated early given that the first four patients enrolled have experienced Grade 4 neutropenia and alopecia after cycle 1 and as such failed to meet the primary endpoint and the main secondary endpoint.
- **Last updated:** 2023-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05622058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05622058, "A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05622058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*